MedTrace Logo

Exercise Training as a Novel Primary Therapy for Men With Localised Prostate Cancer

NCT02409212 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 50

Last updated 2019-01-30

No results posted yet for this study

Summary

Study design: The study is a two arm randomised controlled trial (randomisation ratio 1:1) comparing an aerobic exercise training intervention to usual care plus exercise advice. The primary outcome is the feasibility of the intervention as novel primary therapy in men with localised prostate cancer.

Conditions

Interventions

BEHAVIORAL

Aerobic exercise training

Aerobic exercise training will be undertaken for 12 months, combining supervised and independent exercise sessions. Behaviour change counselling will take place bi-monthly, either via face to face sessions during exercise or via telephone by study clinical exercise specialist according to participant preference.

BEHAVIORAL

Placebo surveillance and written exercise guidelines

Optimal active surveillance according to NICE guidelines and written exercise guidelines from Macmillan cancer

Sponsors & Collaborators

  • Sheffield Hallam University

    collaborator OTHER

  • University of Sheffield

    collaborator OTHER

  • Queen Mary University of London

    collaborator OTHER

  • University College London Hospitals

    collaborator OTHER

  • Institute of Cancer Research, United Kingdom

    collaborator OTHER

  • Sheffield Teaching Hospitals NHS Foundation Trust

    lead OTHER

Principal Investigators

  • Derek Rosario, MD · University of Sheffield / Sheffield Teaching Hospitals

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-05-31
Primary Completion
2018-12-31
Completion
2018-12-31

Countries

  • United Kingdom

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02409212 on ClinicalTrials.gov